We are live on
!
Find out more
B
Bellecapital Portfolio holdings
AUM
$625M
1-Year Est. Return
39.69%
This Fund
S&P 500
This Quarter
Est. Return
+15.6%
1 Year Est. Return
+39.69%
3 Year Est. Return
+127.77%
5 Year Est. Return
+155.51%
10 Year Est. Return
+530.88%
AUM
$300M
AUM Growth
+$81.3M
(+37%)
Cap. Flow
+$53.7M
Cap. Flow
% of AUM
17.92%
Top 10 Holdings %
Top 10 Hldgs %
30.67%
Holding
195
New
35
Increased
77
Reduced
34
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$7.21M |
| 2 |
Tencent Music
TME
|
+$6.16M |
| 3 |
MakeMyTrip
MMYT
|
+$5.61M |
| 4 |
ZTO Express
ZTO
|
+$5.17M |
| 5 |
Health Catalyst
HCAT
|
+$3.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$5.96M |
| 2 |
SPDR Gold Trust
GLD
|
+$1.3M |
| 3 |
BSJK
Invesco BulletShares 2020 High Yield Corporate Bond ETF
BSJK
|
+$1.29M |
| 4 |
IBDL
iShares iBonds Dec 2020 Term Corporate ETF
IBDL
|
+$935K |
| 5 |
Clorox
CLX
|
+$765K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.52% |
| 2 | Consumer Discretionary | 15.83% |
| 3 | Healthcare | 10% |
| 4 | Communication Services | 9.83% |
| 5 | Consumer Staples | 8.36% |
Similar funds
SGA
DCA
SIM
WCAMG
LWM
AGWCA
MWP
KCG
Bellecapital's Q4 2020 Portfolio in Review
As of Q4 2020, Bellecapital held 195 positions worth $300M, up 37% from $219M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Bellecapital deployed $53.7M of net new capital in Q4 2020, opening 35 new positions and adding to 77 existing holdings. Its largest new stake was ARK Genomic Revolution ETF: 90,517 shares worth $8.44M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was SPDR Gold Trust, an estimated $1.3M trimmed.
- Bellecapital's largest Q4 2020 buy was ARK Genomic Revolution ETF: 90,517 shares worth $8.44M.
- Bellecapital added most to ZTO Express in Q4 2020, an estimated $5.17M increase.
- Bellecapital's biggest Q4 2020 reduction was SPDR Gold Trust, cutting an estimated $1.3M.
- Bellecapital fully exited iShares Biotechnology ETF in Q4 2020, selling an estimated $5.96M.
- Bellecapital's ten largest holdings make up 31% of its $300M portfolio in Q4 2020.
- Bellecapital opened 35 new positions and closed 15 in Q4 2020.
- Bellecapital's portfolio value rose 37% quarter-over-quarter to $300M.
Based on Bellecapital's 13F filing for Q4 2020, filed 14 Jan 2021.